European Commission approves Sobi’s Aspaveli for the treatment of C3G and primary IC-MPGN: Stockholm Monday, January 19, 2026, 10:00 Hrs [IST] Sobi, a global biopharma company u ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback